Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 250-284-7 | CAS number: 30674-80-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 21 Sep 2021 - 01 Mar 2022
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 022
- Report date:
- 2022
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- adopted in 2018
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 2-isocyanatoethyl methacrylate
- EC Number:
- 250-284-7
- EC Name:
- 2-isocyanatoethyl methacrylate
- Cas Number:
- 30674-80-7
- Molecular formula:
- C7H9NO3
- IUPAC Name:
- 2-isocyanatoethyl methacrylate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Hino Breeding Center, Charles River Laboratories Japan
- Age at study initiation: 11 weeks (males) and 10 and 11 weeks (females)
- Weight at study initiation: 346.4 - 413.7 g (males) and 203.1 - 253.6 (females; 203.1 - 230.6 g at 10 weeks of age, 215.9 - 253.6 g at 11 weeks of age)
- Housing: In hanging-type stainless wire mesh cages measuring 226 x 346 x 198 mm. Equipment for animal enrichment such as nesting materials, gnawing materials and rest boards were placed in each cage. During quarantine and acclimatisation, 2-3 animals of the same sex were housed in the same cage. During mating males and females were housed 1:1/cage, thereafter the animals were housed 1 female/cage or 1 male/cage.
- Diet: Pellet diet for experimental animals (CRF-1, Oriental Yeast Co., Ltd.), ad libitum
- Water: Well water, admixed with sodium hypochlorite (0.2 ppm), ad libitum
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 - 24.8
- Humidity (%): 42.3 - 69.6
- Air changes (per hr): 10 - 20
- Photoperiod (hrs dark / hrs light): 12 / 12
IN-LIFE DATES: 21 Sep - 19 Oct 2021
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was accurately weighed in a beaker and the property of vehicle was added and stirred with a magnetic stirrre to dissolve. Confirming the dissolution, the total volume was transferred to a measuring cylinder. The vehicle was added and mixed by end-over-end rotation to make a prescribed concentration. After preparation, the dosing formulation was divided into brown glass vials and the vials were filled with nitrogen gas.
Dosing formulations were prepared once every 2 to 3 days.
Storage temperature: The dosing formulations after preparation were divided into glass vials for each dosing day, and stored in a cold place, shielded from light in a glass vial filled with nitrogen gas (actual temperature: 3.5°C to 6.2°C, permissible range: 1°C to 15°C, storage area: in a medical refrigerator.
VEHICLE
- Concentration in vehicle: 1.75, 7.75 and 27.5 mg/mL
- Amount of vehicle: 4 mL/kg bw - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Stability of the test item in the vehicle was demonstrated in a separate study for the concentration levels 1 and 250 mg/mL (Study no. P210104). The formulations at 1 mg/mL were confirmed to be stable for 3 days in a cold place, followed by the storage period of 4 hours at room temperature in nitrogen-filled brown glass vessels. The test article formulations at 250 mg/mL were confirmed to be stable for 8 days in a cold place, followed by the storage period of 4 hours at room temperature in nitrogen-filled brown glass vessels.
- Details on mating procedure:
- - Impregnation procedure: cohoused
- Mating was started at 12 weeks of age. Males and females were housed on a 1:1 base day and night.
- Proof of pregnancy: vaginal plug or sperm in vaginal smear taken in the morning, referred to as Day 0 of gestation (GD 0). - Duration of treatment / exposure:
- Gestation Days 6 - 19
- Frequency of treatment:
- daily, 7 days/week
- Duration of test:
- Day 20 of gestation
Doses / concentrationsopen allclose all
- Dose / conc.:
- 7 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 31 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 110 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 20
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were set based on the results of a preliminary dose range-finding study for prenatal developmental oral toxicity in rats which was conducted at the same testing facility. The animals were dosed at 0, 11, 110, 330 and 1000 mg/kg bw/day. Death and moribundity occurred at 330 mg/kg bw/day or more, and low body weight of the live male and female fetuses were noted at 330 mg/kg bw/day. At 110 mg/kg bw/day, low body weight and food consumption were noted in dams, while no effects on embryo/fetal development was noted. At necropsy, reddish patch in the mucosa of the forestomach was observed at 11 mg/kg bw/day and depressed patch in the mucosa of the forestomach was observed at 110 and 330 mg/kg bw/day, suggesting irritation of the test article to the stomach. Therefore, the high dose level of the present study was set at 110 mg/kg bw/day which was expected to develop some toxicity but not to occur death and severe suffering. The middle and low dose levels were set at 31 and 7 mg/kg bw/day, respectively, with a common ratio of about 4.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Clinical signs and mortality were observed twice a day (before dosing and after dosing) during the dosing period and once a day during the other periods.
- Cage side observations included: mortality and clinical signs
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights were measured on GDs 0, 3, 6, 9, 12, 15, 18, and 20.
FOOD CONSUMPTION: Yes
Food consumption was weighed on GDs 0 to 1, 2 to 3, 5 to 6, 8 to 9, 11 to 12, 14 to 15, 17 to 18, and 19 to 20.
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION: No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: Ovaries and uterus. To investigate the effects of the test substance on the stomach and intestinal tract in more detail, histopathological examination was also performed for nasal cavity, larynx, trachea, lungs, esophagus, stomach, duodenum,jejunum, ileum, cecum, colon, or rectum in dams.
OTHER:
Thyroid Hormone analysis:
- Time schedule for collection of blood: Blood samples were collected from the subclavian vein at scheduled necropsy on gestation Day 20.
- Anaesthetic used for blood collection: No
- How many animals: all pregnant animals in all groups
- Parameters examined: triiodothyronine (T3), thyroxin (T4) and thyroid stimulating hormone (TSH) - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Blood sampling:
- - Plasma: Yes
- Serum: No
- Volume collected : 1.5 mL - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: No
- Anogenital distance of all live rodent pups: Yes: all per litter - Statistics:
- Details on statistics are listed in the field "Any other information on materials and methods incl. tables".
- Indices:
- Pre-implantation loss index: [(Number of corpora lutea - number of implantations) / number of corpora lutea] × 100
Post-implantation loss index: [(Number of implantations - number of live foetuses)/ number of implantations)] × 100
Early resorption index: (Number of early resorptions / number of implantations) × 100
Late resorption index: (Number of late resorptions / number of implantations) × 100
Dead foetus index: (Number of dead foetuses / number of implantations) × 100
Incidence of foetuses with external anomalies (by type of anomaly): [Number of foetuses with anomalies (by type of anomaly) / number of foetuses examined] × 100
Incidence of foetuses with placental anomalies (by type of anomaly): [Number of placentas with anomalies (by type of anomaly) / number of placentas examined] × 100
Incidence of foetuses with skeletal anomalies (by type of anomaly): [Number of foetuses with anomalies (by type of anomaly) / number of foetuses examined] × 100
Incidence of foetuses with skeletal variations (by type of anomaly): [Number of foetuses with variations (by type of variation) / number of foetuses examined] × 100
Incidence of foetuses with visceral anomalies (by type of anomaly): [Number of foetuses with anomalies (by type of anomaly) / number of foetuses examined] × 100
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- At 110 mg/kg bw/day, 16/20 dams showed loose stool from GD 7-19 and 15/20 dams showed salivation from GD 11-19. The findings were noted after dosing and salivation disappeared by the following day. There were no findings at lower dose levels. For details, please refer to Table 1 under "Attachments", PDF document on result tables.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- No maternal death occurred at any dose level.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- There was a statistically significant decrease in body weight noted for the high dose group on GD 12-20 (-4, -5, -7 and -7% at GD 12, 15, 18 and 20). The finding was in line with a reduced food intake in these animals from GD 8-19.
For details, please refer to Table 2 under "Attachments", PDF document on result tables. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- There was a statistically significant decrease in food consumption noted for the high dose group on GD 8-19 (-14, -15, -11, -15 and -10% at GD 9, 11, 14, 17 and 19). The finding was in line with a reduced body weight gain in these animals from GD 12-20.
For details, please refer to Table 3 under "Attachments", PDF document on result tables. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Endocrine findings:
- not specified
- Description (incidence and severity):
- The following ED-related parameters were investigated in the study: T3, T4 and TSH level, anogenital distance, genital abnormalities, thyroid weight, gravid uterus weight, foetal development, litter size, litter/pup weight, number of implantations/ corpora lutea, number of embryonic or foetal deaths and viable foetuses, post-implantation losses, pre-implantation losses, presence of foetal anomalies (external, visceral and skeletal) and sex ratio.
For details, please refer to the respective result fields and the endpoint summary. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No statistically significant difference was observed in either absolute or relative thyroid weight between the control and any test article treatment group.
For details, please refer to Tables 4 and 5 under "Attachments", PDF document on result tables. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Depressed patch in the mucosa of the forestomach was noted in 3/20 dams at 31 mg/kg bw/day and in 17/20 dams at 110 mg/kg bw/day. The findings were in line with histopathological alterations and considered treatment-related.
For details, please refer to Table 6 under "Attachments", PDF document on result tables. - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- In the stomach, hyperplasia of squamous cells and inflammatory cell infiltrate in the forestomach were observed at ≥ 7 mg/kg bw/day. Erosion/ulcer of the forestomach was observed at ≥ 31 mg/kg bw/day. Hypertrophy of mucous neck cells in the glandular stomach was observed in the 110 mg/kg bw/day group. The changes are indicative of a local direct irritancy of the test item and attributed to treatment.
In the larynx and trachea, erosion/ulcer, focal regeneration of mucosal epithelium, and inflammatory cell infiltrate in the mucosa were observed in the 110 mg/kg bw/day group. These changes were considered irritant changes due to direct exposure of the test article by gavage-related reflux.
For details, please refer to Table 7 under "Attachments", PDF document on result tables. - Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- Thyroid hormone analysis revealed no treatment-related changes in any group. Although plasma TSH concentrations at 110 mg/kg bw/day were statistically significantly increased when compared to control animals (+14%), the values were comparable to the historical control values generated in the testing facility. In addition, no treatment-related changes were observed in the thyroid at histopathological examination.
For details, please refer to Tables 8 and 9 under "Attachments", PDF document on result tables.
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Description (incidence and severity):
- No abortion occurred during the study.
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- For details on cesarean section data, please refer to Table 10 under "Attachments", PDF document on result tables.
- Total litter losses by resorption:
- not specified
- Early or late resorptions:
- no effects observed
- Description (incidence and severity):
- For details on cesarean section data, please refer to Table 10 under "Attachments", PDF document on result tables.
- Dead fetuses:
- no effects observed
- Description (incidence and severity):
- For details on cesarean section data, please refer to Table 10 under "Attachments", PDF document on result tables.
- Changes in pregnancy duration:
- not examined
- Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- The number of pregnant animals in the control, 7, 31, and 110 mg/kg bw/day groups was 20, 20, 20, and 17, respectively.
Effect levels (maternal animals)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- maternal toxicity
- Effect level:
- 31 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: no adverse effects observed
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- maternal toxicity
- Effect level:
- 110 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- clinical signs
- food consumption and compound intake
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- local toxicity
- Effect level:
- < 7 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: no adverse effects observed
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- local toxicity
- Effect level:
- 7 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- histopathology: non-neoplastic
Maternal abnormalities
- Key result
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- For details on cesarean section data, please refer to Table 10 under "Attachments", PDF document on result tables.
- Reduction in number of live offspring:
- no effects observed
- Description (incidence and severity):
- For details on cesarean section data, please refer to Table 10 under "Attachments", PDF document on result tables.
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- For details on cesarean section data, please refer to Table 10 under "Attachments", PDF document on result tables.
- Changes in litter size and weights:
- no effects observed
- Description (incidence and severity):
- For details on cesarean section data, please refer to Table 10 under "Attachments", PDF document on result tables.
- Anogenital distance of all rodent fetuses:
- no effects observed
- Description (incidence and severity):
- No statistically significant difference was observed in AGD or AGI between the control and any test article treatment group.
For details on cesarean section data, please refer to Table 10 under "Attachments", PDF document on result tables. - Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Description (incidence and severity):
- No abnormalities were observed in any fetus. Also no placental abnormalies were observed.
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No skeletal anomalies were observed at 110 mg/kg bw/day. In the control group, skeletal anomalies were observed in 1 fetus (0.6%). With regard to individual types of skeletal anomalies, hemicentric thoracic centrum was observed in 1 fetus (0.6%).
Skeletal variations were observed in 24 fetuses (17.2%) and 19 fetuses (14.3%) in the control and 110 mg/kg bw/day groups, respectively. With regard to individual types of skeletal variations, the following findings were observed in the control and 110 mg/kg bw/day groups: bipartite ossification of thoracic centrum in 2 fetuses (1.3%) and 1 fetus (0.7%), full supernumerary rib in 3 fetuses (2.5%) and 2 fetuses (1.4%), short supernumerary rib in 16 fetuses (11.9%) and 13 fetuses (9.7%), asymmetry of the sternebra in 2 fetuses (1.3%) and 3 fetuses (2.4%), and bipartite ossification of sternebra in 5 fetuses (3.4%) and 1 fetus (0.7%), respectively. However, no statistically significant differences were observed in their incidences between the control and 110 mg/kg bw/day groups. Additionally, all effects observed in the 110 mg/kg bw/day group were seen in the control group with a similar frequency. The findings of bipartite ossification of supraoccipital bone in 1 fetus (0.6%) and 7 lumbar vertebrae in 1 fetus (1.0%) were observed only in the control group.
In addition, no statistically significant differences were observed in the number of sacrocaudal vertebral bodies or sternebrae between the control and 110 mg/kg bw/day groups.
The findings on skeletal anomalies and variations were not attributed to treatment.
For details on litter data, please refer to Table 11 under "Attachments", PDF document on result tables. - Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Visceral anomalies were observed in 5 fetuses (4.0%) and 1 fetus (0.9%) in the control and 110 mg/kg bw/day groups, respectively. With regard to individual types of visceral anomalies, thymic remnant in the neck was observed in 1 fetus (0.9%) in the 110 mg/kg bw/day group. However, this change was also observed in the control group [4 fetuses (3.0%)]. The finding dilated renal pelvis and dilated ureter were observed in 1 fetus (1.0%) was observed only in the control group. The observations were not attributed to treatment.
For details on litter data, please refer to Table 12 under "Attachments", PDF document on result tables.
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- developmental toxicity
- Effect level:
- >= 110 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed
- Remarks on result:
- other: corresponding to the highest dose level tested
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- The test item had no effect on intrauterine development. The NOAEL for developmental toxicity was ≥ 110 mg/kg bw/day.
The NOAEL for maternal toxicity was 31 mg/kg bw/day, based on clinical signs of toxicity, reduced food consumption and impaired body weight development at 110 mg/kg bw/day.
The NOAEL for local toxicity was < 7 mg/kg bw/day, based on hyperplasia of squamous cells in the stomach and inflammatory cell infiltrate in the forestomach at ≥7 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.